Kidney Cancer Journal 103
gene UTX in human cancer. Nat Genet. 2009;41(5):521-3.
27. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A,
et al. Systematic sequencing of renal carcinoma reveals inactivation of
histone modifying genes. Nature. 2010;463(7279):360-3.
28. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al.
Exome sequencing identifies frequent mutation of the SWI/SNF complex
gene PBRM1 in renal carcinoma. Nature. 2011;469(7331):539-42.
29. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez
A, Wang S, et al. BAP1 loss defines a new class of renal cell carcinoma.
Nature Genetics. 2012;44:751.
30. de Cubas AA, Rathmell WK. Epigenetic modifiers: activities in renal
cell carcinoma. Nature Reviews Urology. 2018;15(10):599-614.
31. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A,
Rathmell WK, et al. Effects on survival of BAP1 and PBRM1 mutations
in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with
independent validation. The Lancet Oncology. 2013;14(2):159-67.
32. Pena-Llopis S, Christie A, Xie XJ, Brugarolas J. Cooperation and antagonism
among cancer genes: the renal cancer paradigm. Cancer Res.
2013;73(14):4173-9.
33. Cancer Genome Atlas Research N. Comprehensive molecular characterization
of clear cell renal cell carcinoma. Nature. 2013;499(7456):
43-9.
34. Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC,
et al. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and
PBRM1 Expression. J Urol. 2016;195(1):180-7.
35. Joseph RW, Kapur P, Serie DJ, Eckel-Passow JE, Parasramka M, Ho
T, et al. Loss of BAP1 protein expression is an independent marker of
poor prognosis in patients with low-risk clear cell renal cell carcinoma.
Cancer. 2014;120(7):1059-67.
36. Kapur P, Christie A, Raman JD, Then MT, Nuhn P, Buchner A, et al.
BAP1 immunohistochemistry predicts outcomes in a multi-institutional
cohort with clear cell renal cell carcinoma. J Urol. 2014;191(3):
603-10.
37. Gu YF, Cohn S, Christie A, McKenzie T, Wolff N, Do QN, et al. Modeling
Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation
Drive Tumor Grade. Cancer Discov. 2017;7(8):900-17.
38. Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy
A, et al. Clinical and pathologic impact of select chromatin-modulating
tumor suppressors in clear cell renal cell carcinoma. Eur Urol. 2013;63
(5):848-54.
39. Carlo MI, Manley B, Patil S, Woo KM, Coskey DT, Redzematovic A,
et al. Genomic Alterations and Outcomes with VEGF-Targeted Therapy
in Patients with Clear Cell Renal Cell Carcinoma. Kidney Cancer.
2017;1(1):49-56.
40. Voss MH, Reising A, Cheng Y, Patel P, Marker M, Kuo F, et al. Genomically
annotated risk model for advanced renal-cell carcinoma: a
retrospective cohort study. The Lancet Oncology. 2018;19(12):1688-98.
41. Espana-Agusti J, Warren A, Chew SK, Adams DJ, Matakidou A. Loss
of PBRM1 rescues VHL dependent replication stress to promote renal
carcinogenesis. Nat Commun. 2017;8(1):2026.
42. Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie
Y, et al. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear
Cell Renal Cell Carcinoma. Cell Rep. 2017;18(12):2893-906.
43. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM,
et al. Patterns of gene expression and copy-number alterations in vonhippel
lindau disease-associated and sporadic clear cell carcinoma of
the kidney. Cancer Res. 2009;69(11):4674-81.
44. Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, et al.
Genome-wide profiling of chromosomal alterations in renal cell carcinoma
using high-density single nucleotide polymorphism arrays. Int J
Cancer. 2009;125(10):2342-8.
45. Kucejova B, Pena-Llopis S, Yamasaki T, Sivanand S, Tran TA, Alexander
S, et al. Interplay between pVHL and mTORC1 pathways in clearcell
renal cell carcinoma. Molecular Cancer Research: 2011;9(9): 1255-65.
46. Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell
carcinoma: findings and clinical implications. Nature Reviews Urology.
2019.
47. Durinck S, Stawiski EW, Pavia-Jimenez A, Modrusan Z, Kapur P,
Jaiswal BS, et al. Spectrum of diverse genomic alterations define nonclear
cell renal carcinoma subtypes. Nat Genet. 2015;47(1):13-21.
48. Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis
C, et al. Comprehensive Molecular Characterization of Papillary Renal-
Cell Carcinoma. The New England journal of Medicine. 2016;374(2):135-
45.
49. Ooi A, Wong J-C, Petillo D, Roossien D, Perrier-Trudova V, Whitten
D, et al. An antioxidant response phenotype shared between hereditary
and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011;
20(4):511-23.
50. Ooi A, Dykema K, Ansari A, Petillo D, Snider J, Kahnoski R, et al.
CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a
sporadic form of papillary renal cell carcinoma. Cancer Research.
2013;73(7):2044-51.
51. Brunelli M, Eble JN, Zhang S, Martignoni G, Delahunt B, Cheng L.
Eosinophilic and classic chromophobe renal cell carcinomas have similar
frequent losses of multiple chromosomes from among chromosomes
1, 2, 6, 10, and 17, and this pattern of genetic abnormality is
not present in renal oncocytoma. Mod Pathol. 2005;18(2):161-9.
52. Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, et
al. The somatic genomic landscape of chromophobe renal cell carcinoma.
Cancer Cell. 2014;26(3):319-30.
53. Chen F, Zhang Y, Senbabaoglu Y, Ciriello G, Yang L, Reznik E, et al.
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell
Rep. 2016;14(10):2476-89.
54. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H.
An outcome prediction model for patients with clear cell renal cell carcinoma
treated with radical nephrectomy based on tumor stage, size,
grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395-400.
55. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al.
Risk group assessment and clinical outcome algorithm to predict the
natural history of patients with surgically resected renal cell carcinoma.
J Clin Oncol. 2002;20(23):4559-66.
56. Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM,
et al. Predicting Renal Cancer Recurrence: Defining Limitations of Existing
Prognostic Models With Prospective Trial-Based Validation. J Clin
Oncol. 2019;37(23):2062-71.
57. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al.
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell
carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled,
randomised, phase 3 trial. The Lancet. 2016;387(10032):2008-16.
58. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferonalfa
as a comparative treatment for clinical trials of new therapies
against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289-96.
59. Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C,
et al. Prognostic Factors for Overall Survival in Patients With Metastatic
Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–
Targeted Agents: Results From a Large, Multicenter Study. J Clin
Oncol. 2009;27(34):5794-9.
60. Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Tong P, et al.
Loss of histone H3 lysine 36 trimethylation is associated with an increased
risk of renal cell carcinoma-specific death. Mod Pathol. 2016;
29(1):34-42.
61. Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, et
al. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus
Clustering Reveals Distinct Subtypes and Survival Patterns.
Genes Cancer. 2010;1(2):152-63.
62. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, et
al. ClearCode34: A prognostic risk predictor for localized clear cell renal
cell carcinoma. European Urology. 2014;66(1):77-84.
63. de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir
NM, et al. Molecular Subtypes Improve Prognostic Value of International
Metastatic Renal Cell Carcinoma Database Consortium Prognostic
Model. The Oncologist. 2017;22(3):286-92.
64. Hakimi AA, Voss MH, Kuo F, Sanchez A, Liu M, Nixon BG, et al.
Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct
Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized
Phase III Trial. Cancer Discov. 2019;9(4):510-25.
65. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar
B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in
Advanced Renal-Cell Carcinoma. New England Journal of Medicine.
2018;378(14):1277-90.
66. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell
Carcinoma. New England Journal of Medicine. 2019;380(12):1116-27.
67. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier
B, et al. Clinical activity and molecular correlates of response to atezolizumab
alone or in combination with bevacizumab versus sunitinib
in renal cell carcinoma. Nature Medicine. 2018;24(6):749-57.
68. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al.
Systematic RNA interference reveals that oncogenic KRAS-driven cancers
require TBK1. Nature. 2009;462(7269):108.
69. Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, et al.
An Empirical Approach Leveraging Tumorgrafts to Dissect the
Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing
Link to Prognostic Inflammatory Factors. Cancer Discov. 2018;8(9):
1142-55.
70. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers
for checkpoint inhibitor immunotherapy. Nature Reviews Cancer.
2019;19(3):133-50.
71. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder
D, et al. Intratumor heterogeneity and branched evolution revealed by